| 摘要 |
The present invention relates to a compound of the formula: <See formula I> (wherein n is 0-6; Z is (C1-C4)alkylene, oxygen, sulfur, NH or N(C1,-C6)alkyl; R1 is hydrogen, cyclohexyl (C1-C6)alkyl, aryl or heteroaryl, wherein the aryl is selected from phenyl and naphthyl and the heteroaryl is selected from 5 and 6 membered aromatic heterocyclic rings that contain from one to four heteroatoms selected, independently, from nitrogen, oxygen and sulfur, and wherein the aryl and heteroaryl moieties may optionally be substituted with one or more substituents selected, independently, from halo, -SO(C1-C6)alkyl, -SO2R4, -SO2NR5R6, (C1-C6)alkyl optionally substituted with from one to seven fluorine atoms, (C1-C6)alkoxy optionally substituted with from one to seven fluorine atoms, amino, nitro, cyano, carboxy, -CO2(C1-C6)alkyl, (C1-C6)alkylamino, di-[(C1-C6)alkyl]amino phenoxy, anilino and phenylthio; R4 is -O(C1-C6)alkyl, phenyl or (C1-C6)alkyl; and R5 and R6 are selected, independently, from hydrogen, (C1-C6)alkyl and phenyl; with the proviso that (a) R1 cannot be hydrogen when n is zero, and (b) none of the foregoing heteroaryl moieties may contain more than one ring oxygen atom or more than one ring sulfur atom) or a pharma- ceutically acceptable salt thereof; a pharmaceutical composition containing such a compound; and the use of such compound to treat neurological and psychiatric disorders.
|
